News

The CHMP positive opinion will be reviewed by the European Commission, which if approved, grants a centralized marketing authorization with unified labeling that is valid in the 28

The two distinct properties could result in a unique therapeutic profile for SYN120 combining pro-cognitive and antipsychotic activities. SYN120 has completed single and multiple ascending dose Phase I

The company also announced a $15m investment by Perrigo to acquire approximately 7% of Transition’s common shares. ELND005 is an oral drug candidate that is being evaluated in

Otsuka, in accordance with the MOU, has engaged in a wide range of capital expenditures for the manufacture of pharmaceutical products, including investment in research and development of

Discovered by Takeda, TAK-438 belongs to a new class of inhibitors called potassium-competitive acid blockers (P-CABs) that show strong and sustainable acid secretion inhibitory effects as well as

Building upon over a decade of experience as the leading gene synthesis supplier in the US, GenScript has developed a new breakthrough technology: GenPlus Next-Generation Gene Synthesis. GenPlus

The placebo-controlled trial is designed to evaluate the safety and efficacy of OIT and CPNA as a prescribed treatment for patients with peanut allergy to follow under the

The option agreement with GW adds potential proprietary protection to the company’s pipeline, which includes treatments for chronic kidney disease, hepatorenal syndrome, chronic iron overload, and rare diseases.

Invasive mucormycosis is a life-threatening invasive fungal infection caused by certain emerging molds. The designation provides priority review and a five-year extension of market exclusivity in the US.